Page 21 of 39 · 913 questions tagged clinical-trials.
Stated plainly: orforglipron · tirzepatide. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain either…
Stated plainly: dulaglutide · 4 °C. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have searched the…
Conditions: SURPASS-3 · dizziness · 60 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
The case in front of me: survodutide · 30 °C. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and…
The particulars: FLOW · headache. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…
For reference: SURMOUNT-1 · survodutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
The specifics, since they change the answer: SURMOUNT-1 · 5 mg. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I…
The particulars: eight weeks · semaglutide. I would like to know whether this claim survives contact with evidence. If the answer is "nobody has tested that", I would…
Numbers first: reflux · orforglipron · TRIUMPH-3. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone…
Concretely: 40 mg · liraglutide. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I would like the plan to…
The obesity pipeline is currently full of phase 2 results being quoted as though they were established magnitudes. Retatrutide at -24.2% over 48 weeks is the…
Setup, so nobody has to ask: ESSENCE · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the…
The specifics, since they change the answer: liraglutide · semaglutide. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read…
Setup, so nobody has to ask: SURPASS-3 · injection-site erythema · 40 mg. I have read the primary source rather than the summary, which has left me with more…
Conditions: nausea · oral semaglutide · SUSTAIN-6. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a…
What I am working with: STEP 8 · cagrilintide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
Conditions: SUSTAIN-6 · liraglutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result,…
Stated plainly: retatrutide · ATTAIN-1. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody knows, I would rather hear…
My background is chemistry rather than physiology, which may explain where I am stuck. This has the shape of a fact but I cannot find its origin. What I found instead…
Details up front: ESSENCE · orforglipron. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am…
I would like to know how much of this is established and how much is a reasonable story. I want to know what the trade-off actually is rather than which option is…
Stated plainly: REDEFINE-1 · 15 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do not…
The case in front of me: semaglutide · TRIUMPH-1. This is one of those things that everyone repeats and nobody derives. This matters practically, not just…
What I am working with: STEP 8 · cagrilintide. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all citing…